Results 71 to 80 of about 12,890,416 (254)

Bridging the gap: a genetically validated avian chorioallantoic membrane platform for investigation of spontaneous circulating tumor cells

Molecular Oncology, EarlyView.
We established the avian chorioallantoic membrane (CAM) assay as a scalable in vivo model for studying circulating tumor cells (CTCs). Human gastrointestinal tumors spontaneously released genetically validated CTCs that were detected across multiple platforms, demonstrating that the CAM model provides an accessible tool for investigating early cancer ...
Dennis Roth, Rui P. L. Neves, Julia Geheb, Christian Ballmeyer, Nathalie Gaßmann, Kiki C. Andree, Monica Sudarsanam, Christiane Driemel, Celine Örencik, Andrè Franken, Eslam Elmaghraby, Sven H. Loosen, Roderburg Christoph, Sebastian Schoelch, Hans Neubauer, Wolfram T. Knoefel, Nikolas H. Stoecklein, Georg Fluegen   +17 more
wiley   +1 more source

An Estimate of the proportion of symptoms reported in Self-administered questionnaires that are captured as adverse drug events in an observational database [PDF]

, 2007
Purpose: This study was conducted to determine how frequently self-reported symptoms are captured as adverse drug events (ADEs) during chart abstraction.
Walmsley, S., Raboud, J., Bayoumi, A., Phillips, E.J., Sterling, S., Lesosky, M.   +5 more
core  

Treatment with KCL‐286, a first‐in‐class retinoic acid receptor‐β (RARβ) agonist, ameliorates neuronal DNA damage and inflammation in a mouse model of Alzheimer's disease

FEBS Open Bio, EarlyView.
Repair of neuronal DNA damage in Alzheimer's disease by KCL‐286. (A) Amyloid‐β oligomers and plaques impair neuronal DNA repair pathways, leading to DNA double‐strand breaks and glial activation. (B) KCL‐286 activates RARβ/RXR signalling via retinoic acid response elements (RAREs), associated with increased BRCA1 expression, enhanced DNA repair and ...
Natasha Hill, Hassan Yousef Othman AlMuallim, Elouisa Maddock, Carl Hobbs, Earl Clarke, Maria B. Goncalves, Jonathan P. T. Corcoran   +6 more
wiley   +1 more source

Investigational Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Event Prediction and Diagnosis

, 2020
BACKGROUND: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of multiple cancers. However, these promising therapies may also cause immune-related adverse events (irAEs) in a substantial proportion of patients.
Gerber, David E, Khan, Shaheen, von Itzstein, Mitchell S   +2 more
core   +1 more source

Dermatologic toxicities related to cancer immunotherapy

Toxicology Reports
Immunotherapy has revolutionized cancer treatment, offering significant survival superiority for advanced malignancies. However, immunotherapy is associated with various immune-related adverse events, one of the most common of them being dermatologic ...
Yosra Vaez-Gharamaleki, Mohammad Amin Akbarzadeh, Farhad Jadidi-Niaragh, Ata Mahmoodpoor, Sarvin Sanaie, Mohammad-Salar Hosseini   +5 more
doaj   +1 more source

GelMA‐based 3D spheroids recapitulate transcriptomic and functional hallmarks of myeloid sarcoma

FEBS Open Bio, EarlyView.
GelMA 5% hydrogels support the formation of myeloid leukemia spheroids that recapitulate MS‐specific features, including G1 arrest, apoptosis, and ECM‐driven transcriptomic reprogramming. The 3D model mimicked soft‐tissue‐like stiffness and oxygen conditions, and transcriptomic convergence with primary MS samples confirmed its utility as a preclinical ...
Nicolas Germain, Elise Buret, Le Hoang Thanh Nguyen, Marion Cocheteux, Nicolas Touya, Mélanie Dhayer, Romain Dubois, Frank Lafont, Sebastien Janel, Patrice Maboudou, Steve Lancel, Philippe Marchetti   +11 more
wiley   +1 more source

Understanding and Mitigating the Risk of Accelerated Biological Aging in Survivors of Cancer: A Scoping Review

Aging and Cancer, EarlyView.
Cancer treatment is associated with measurable acceleration of biological aging across epigenetic, telomere, senescence, and immune biomarkers. However, biomarker validation and interventional strategies remain limited, especially in hematologic malignancies, underscoring the need for standardized multi‐omic aging assessments and adequately powered ...
Moataz Ellithi, Emily Herdman, Danielle Westmark, Vijaya R. Bhatt   +3 more
wiley   +1 more source

Neurological Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors

Biomedicines
The use of immune checkpoint inhibitors (ICIs) for the treatment of various advanced and aggressive types of malignancy has significantly increased both survival and long-term remission rates.
Sotiria Stavropoulou De Lorenzo, Athina Andravizou, Harry Alexopoulos, Iliana Michailidou, Alexandros Bokas, Evangelia Kesidou, Marina-Kleopatra Boziki, Dimitrios Parissis, Christos Bakirtzis, Nikolaos Grigoriadis   +9 more
doaj   +1 more source

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan, Lei Zhou, Jingzi ZhangBao, Hongmei Tan, Zhouzhou Wang, Chao Quan   +5 more
wiley   +1 more source

The management of nivolumab-induced endocrine immune-related adverse events [PDF]

, 2018
Immune-mediated endocrine adverse events induced by nivolumab therapy are related to the activation of the immunological system, and often they affect the pituitary, thyroid, and pancreas leading to hypophysitis, thyroiditis, and diabetes mellitus.
Zgliczyński, Wojciech, Stelmachowska-Banaś, Maria   +1 more
core   +1 more source